Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Fabhalta Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.36

    Fabhalta (iptacopan) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.36 alerts

    Get alerted when Policy 05.05.36 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of Fabhalta for adults with paroxysmal nocturnal hemoglobinuria, primary immunoglobulin A nephropathy, or complement 3 glomerulopathy, subject to indication-specific clinical criteria, documentation, prescriber specialty requirements, and prior authorization.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyFabhalta (iptacopan) Coverage Criteria
    Policy CodePolicy 05.05.36
    Change TypeNo material clinical or coverage changes
    Effective DateMar 19, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit indication-specific diagnostic confirmation, laboratory findings, and clinical documentation with the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3FDA-approved indications
    6 monthsMaximum initial approval: PNH
    12 monthsMaximum initial approval: IgAN and C3G
    Epysqli or UltomirisPreferred PNH products required before Fabhalta

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60 capsulesQuantity limit

    Coverage Criteria

    Initial therapy: Paroxysmal nocturnal hemoglobinuria

    Covered when all of the following are met.

    Initial PNH criteria

    • Diagnostic confirmation

      • PNH cell threshold: Flow cytometry demonstrates GPI-AP deficiency with either at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells.At least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells
    • Clinical disease: The member has and exhibits clinical manifestations of PNH, such as LDH greater than 1.5 times the upper limit of normal, thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia.
    • Concomitant therapy restriction: Fabhalta will not be used concomitantly with another complement inhibitor for the treatment of PNH.

      Examples include Empaveli, Piasky, eculizumab, and Ultomiris.

    Initial therapy: Primary immunoglobulin A nephropathy

    Covered when all of the following are met.

    Initial IgAN criteria

    • Biopsy confirmation: The diagnosis of primary immunoglobulin A nephropathy is confirmed by kidney biopsy.
    • Age: The member is 18 years of age or older.18 years or older
    • Disease progression risk: The member is at risk for rapid disease progression.UPCR greater than or equal to 1.5 g/g
    • RAS inhibitor requirement:

    Initial therapy: Complement 3 glomerulopathy

    Covered when all of the following are met.

    Initial C3G criteria

    • Biopsy confirmation: The diagnosis of complement 3 glomerulopathy is confirmed by kidney biopsy.
    • Proteinuria: The member has proteinuria or elevated UPCR.Proteinuria greater than or equal to 1 g/day or UPCR greater than or equal to 1 g/g
    • Reduced serum C3: The member has reduced serum C3 at baseline.Less than 0.85 times the lower limit of normal

      Reference ranges provided by the laboratory apply.

    Continuation therapy: Paroxysmal nocturnal hemoglobinuria

    Covered when all of the following are met.

    Continuation PNH criteria

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive response: The member demonstrates a positive response to therapy, such as improvement in hemoglobin levels or normalization of LDH levels.
    • Concomitant therapy restriction: Fabhalta will not be used in combination with another complement inhibitor for the treatment of PNH.

      Examples include Empaveli, Piasky, eculizumab, and Ultomiris.

    Continuation therapy: Primary immunoglobulin A nephropathy

    Covered when all of the following are met.

    Continuation IgAN criteria

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Treatment benefit: The member is benefiting from therapy as demonstrated by decreased proteinuria from baseline or decreased UPCR from baseline.Decrease from baseline

    Continuation therapy: Complement 3 glomerulopathy

    Covered when all of the following are met.

    Continuation C3G criteria

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Treatment benefit: The member is benefiting from therapy as demonstrated by decreased proteinuria from baseline or decreased UPCR from baseline.Decrease from baseline

    Continued C3G therapy

    Fabhalta may be considered medically necessary for continued treatment of C3G when all of the following are met.

    Continued treatment criteria

    • No toxicity or progression: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Evidence of benefit

      • Decreased proteinuria: There is a decrease in levels of proteinuria from baseline.
      • Decreased UPCR: There is a decrease in UPCR from baseline.

    Non-formulary exception

    A non-formulary medication may be covered when the criteria for approval and all of the following are met.

    Non-formulary exception criteria: The requested drug is used for an FDA-approved indication or an indication supported by current literature compendia; the prescribed dose and quantity fall within FDA-approved labeling or compendia dosing guidelines; and all covered formulary alternatives on any tier are ineffective, have been ineffective, would not be as effective as the requested drug, associated with adverse effects, or contraindicated.

    When applicable, submit diagnostic testing or laboratory results. Documentation must address prior treatment failure, adverse-event severity, prior dosage and duration, or contraindication to formulary alternatives.

    For treatment of paroxysmal nocturnal hemoglobinuria (PNH), concurrent use of Fabhalta with another complement inhibitor is excluded. Examples include Empaveli, Piasky, eculizumab, and Ultomiris.

    For primary immunoglobulin A nephropathy (IgAN), Fabhalta must not be used concurrently with Tarpeyo, Vanrafia, Voyxact, or Filspari.

    Members receiving Fabhalta through samples or the manufacturer’s patient assistance program must still meet all criteria for initial approval.

    Fabhalta is considered not medically necessary when the member does not meet the applicable policy criteria.

    Initial Therapy Criteria

    PNH initial therapy

    Initial PNH therapy is covered when all criteria are met.

    • Diagnostic confirmation

      • PNH cell threshold: Flow cytometry demonstrates GPI-AP deficiency with either at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells.At least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells
    • Clinical manifestations: The member has and exhibits clinical manifestations of PNH, such as LDH greater than 1.5 times the upper limit of normal, thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia.
    • Concomitant therapy restriction:

    Continuation Criteria

    PNH continuation

    Continued PNH treatment is covered when all criteria are met.

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive clinical response: The member demonstrates a positive response to therapy, such as improvement in hemoglobin levels or normalization of LDH levels.
    • Concomitant therapy restriction: Fabhalta will not be used in combination with another complement inhibitor for PNH treatment.

      Examples include Empaveli, Piasky, eculizumab, and Ultomiris.

    IgAN continuation

    Diagnostic and Laboratory Thresholds

    PNH cells
    Minimum PNH cell thresholdAt least 5% PNH cells
    Diagnostic purposeUsed to confirm paroxysmal nocturnal hemoglobinuria through detection of GPI-AP deficiency
    Alternative qualifying thresholdAt least 51% GPI-AP-deficient polymorphonuclear cells
    GPI-AP-deficient polymorphonuclear cells
    Minimum percentageAt least 51%
    Cell typeGPI-AP-deficient polymorphonuclear cells
    Diagnostic purposeQualifies as an alternative threshold for confirming PNH

    Prior Authorization and Provider Requirements

    Prior Authorization

    Required Prior Authorization Documentation

    Prior authorization submission must include the indication-specific diagnostic, laboratory, and clinical documentation required for the requested Fabhalta indication. For initial requests, submit the applicable PNH, IgAN, or C3G records; for continuation requests, submit documentation supporting clinical response.

    • PNH: Flow cytometry demonstrating glycosylphosphatidylinositol-anchored protein (GPI-AP) deficiency.
    • IgAN: Kidney biopsy confirming primary IgAN and laboratory report and/or chart notes showing UPCR ≥ 1.5 g/g and risk for disease progression.
    • C3G: Kidney biopsy confirming C3G; proteinuria ≥ 1 g/day or baseline UPCR ≥ 1 g/g; and reduced serum C3.
    • Continuation: PNH chart notes or medical documentation supporting positive clinical response; IgAN laboratory report and/or chart notes supporting positive clinical response; or C3G laboratory report and/or chart notes showing decreased proteinuria or UPCR from baseline.
    Prior Authorization

    Initial Approval Criteria

    Initial approval requires that the member meet all applicable indication-specific medical-necessity criteria. Initial authorization duration is governed by the plan's authorization period; the source criteria do not specify a separate indication-specific duration.

    Clinical Background

    Fabhalta (iptacopan) is indicated for adults with paroxysmal nocturnal hemoglobinuria (PNH), for reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for rapid disease progression, and for reduction of proteinuria in adults with complement 3 glomerulopathy (C3G). Coverage is evaluated using indication-specific diagnostic confirmation, disease activity or proteinuria thresholds, prior and concomitant therapy requirements, and evidence of response for continued treatment.

    Policy Definitions

    PNH diagnostic confirmation
    Diagnostic methodFlow cytometry demonstrates deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs)
    Qualifying PNH cell thresholdAt least 5% PNH cells
    Alternative GPI-AP deficiency thresholdAt least 51% GPI-AP-deficient polymorphonuclear cells
    Reduced serum C3
    DefinitionLess than 0.85 times the lower limit of normal
    TimingThe reduced serum C3 finding is assessed at baseline
    Reference range

    Required Preferred Therapy

    StepIndicationRequired prior therapyFabhalta may be used when
    1Paroxysmal nocturnal hemoglobinuria (PNH)Use Epysqli (eculizumab-aagh) or Ultomiris (ravulizumab) before Fabhalta.The member has an inadequate response, intolerable adverse event, or contraindication to a preferred product, or clinical circumstances exclude use of all preferred products.
    StepIndicationRequired prior therapyFabhalta may be used when
    1Primary immunoglobulin A nephropathy (IgAN)Try and fail Filspari (sparsentan) before Fabhalta.The member has intolerance or a contraindication to Filspari.

    Quantity and Dosing Limits

    Quantity limit
    MedicationFabhalta (iptacopan) 200 mg oral capsule
    Standard quantity limit60 capsules per 30 days
    FDA-recommended dosing200 mg twice daily
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyFabhalta (iptacopan) Coverage Criteria
    Policy CodePolicy 05.05.36
    Change TypeNo material clinical or coverage changes
    Effective DateMar 19, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit indication-specific diagnostic confirmation, laboratory findings, and clinical documentation with the prior authorization request.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaDiagnostic and Laboratory ThresholdsPrior Authorization and Provider RequirementsClinical BackgroundPolicy DefinitionsRequired Preferred TherapyQuantity and Dosing Limits
    The member has received a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months before initiation, or has an intolerance or contraindication to RAS inhibitors.
    At least 3 months

    RAS inhibitors include ACEI or ARB therapy.

  1. Filspari requirement: The member has tried and failed Filspari, or has an intolerance or contraindication to Filspari.
  2. Concomitant therapy restriction: Fabhalta will not be used in combination with Tarpeyo, Vanrafia, Voyxact, or Filspari.
  3. RAS inhibitor requirement: The member has received a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months before initiation, or has an intolerance or contraindication to RAS inhibitors.At least 3 months

    RAS inhibitors include ACEI or ARB therapy.

    Fabhalta will not be used concomitantly with another complement inhibitor for PNH treatment.

    Examples include Empaveli, Piasky, eculizumab, and Ultomiris.

    IgAN initial therapy

    Initial IgAN therapy is covered when all criteria are met.

    • Biopsy confirmation: The diagnosis of primary IgAN is confirmed by kidney biopsy.
    • Age: The member is 18 years of age or older.18 years or older
    • Rapid progression risk: The member is at risk for rapid disease progression.UPCR greater than or equal to 1.5 g/g
    • RAS inhibitor requirement: The member has received a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months before initiation, or has an intolerance or contraindication to RAS inhibitors.At least 3 months

      RAS inhibitors include ACEI or ARB therapy.

    • Filspari requirement: The member has tried and failed Filspari, or has an intolerance or contraindication to Filspari.
    • Concomitant therapy restriction: Fabhalta will not be used in combination with Tarpeyo, Vanrafia, Voyxact, or Filspari.

    C3G initial therapy

    Initial C3G therapy is covered when all criteria are met.

    • Biopsy confirmation: The diagnosis of C3G is confirmed by kidney biopsy.
    • Proteinuria: The member has proteinuria or elevated UPCR.Proteinuria greater than or equal to 1 g/day or UPCR greater than or equal to 1 g/g
    • Reduced serum C3: The member has reduced serum C3 at baseline.Less than 0.85 times the lower limit of normal

      Reference ranges provided by the laboratory apply.

    • RAS inhibitor requirement: The member has received a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months before initiation, or has an intolerance or contraindication to RAS inhibitors.At least 3 months

      RAS inhibitors include ACEI or ARB therapy.

    Continued IgAN treatment is covered when all criteria are met.

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Treatment benefit: The member is benefiting from therapy as demonstrated by decreased proteinuria from baseline or decreased UPCR from baseline.Decrease from baseline

    C3G continuation

    Continued C3G treatment is covered when all criteria are met.

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Treatment benefit: The member is benefiting from therapy as demonstrated by decreased proteinuria from baseline or decreased UPCR from baseline.Decrease from baseline

    Continued treatment for C3G

    Fabhalta may be considered medically necessary for continued treatment of C3G when all of the following are met.

    Continued C3G therapy

    • No toxicity or progression: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Evidence of benefit

      • Decreased proteinuria: There is a decrease in levels of proteinuria from baseline.
      • Decreased UPCR: There is a decrease in UPCR from baseline.
    PNH disease manifestation
    Hemolysis indicatorLDH greater than 1.5 times the upper limit of normal
    Vascular manifestationThrombosis
    Renal manifestationRenal dysfunction
    Pulmonary manifestationPulmonary hypertension
    Other manifestationDysphagia
    IgAN rapid progression risk
    UPCR thresholdGreater than or equal to 1.5 g/g
    Clinical significanceDefines risk for rapid disease progression in primary IgAN
    MeasurementUrine protein-to-creatinine ratio (UPCR)
    C3G proteinuria
    Proteinuria thresholdGreater than or equal to 1 g/day
    UPCR thresholdGreater than or equal to 1 g/g
    Clinical contextApplies to adults with C3G for whom Fabhalta is requested
    C3G serum C3
    Reduced serum C3 thresholdLess than 0.85 times the lower limit of normal
    TimingMeasured at baseline
    Reference standardInterpret according to the laboratory reference ranges provided
    • PNH: Confirmed GPI-AP deficiency, qualifying PNH cell findings, clinical manifestations, and no prohibited concomitant complement inhibitor.
    • IgAN: Biopsy-confirmed disease, age ≥ 18 years, UPCR ≥ 1.5 g/g, stable maximally tolerated RAS inhibitor therapy for at least 3 months or documented intolerance/contraindication, and prior Filspari failure unless intolerance/contraindication exists.
    • C3G: Biopsy-confirmed disease, proteinuria ≥ 1 g/day or UPCR ≥ 1 g/g, reduced baseline serum C3, and stable maximally tolerated RAS inhibitor therapy for at least 3 months or documented intolerance/contraindication.

    Unsupported block type: prior_auth

    Documentation Required

    Continued C3G Treatment Authorization

    For continued C3G treatment, submit documentation showing that the member is tolerating the current regimen without unacceptable toxicity or disease progression and is experiencing measurable benefit.

    • Document decreased proteinuria from baseline or a decreased UPCR from baseline.
    • Provide laboratory reports and/or chart notes supporting the response.
    Step Therapy

    Preferred Therapy Step for PNH

    Fabhalta is non-preferred for PNH. Initial approval requires appropriate use of a preferred product unless clinical circumstances exclude use of all preferred products.

    • Preferred products are Epysqli (eculizumab-aagh) or Ultomiris (ravulizumab).
    • The member must have had an inadequate response, intolerable adverse event, or contraindication to one of the preferred products.
    • Document the clinical circumstance that excludes use of the preferred products when applicable.
    Step Therapy

    Filspari Trial Required for IgAN

    Before Fabhalta is approved for IgAN, the member must have tried and failed Filspari unless the member has an intolerance or contraindication to Filspari.

    • Document prior Filspari treatment failure, or provide documentation of intolerance or contraindication.
    Step Therapy

    Formulary Alternative Review

    For a non-formulary request, meeting the applicable Fabhalta approval criteria may satisfy only part of the exception review. The request must also meet the non-formulary exception requirements.

    • The requested drug must be used for an FDA-approved indication or an indication supported by current compendia or accepted guidelines.
    • The prescribed dose and quantity must be within FDA-approved labeling or compendial dosing guidelines.
    • All covered formulary alternatives must be ineffective, previously ineffective, less effective, or associated with adverse effects, with supporting documentation.
    Documentation Required

    Initial Diagnostic and Laboratory Documentation

    Initial requests must include diagnostic confirmation and the required laboratory results for the requested indication. Submit laboratory reports and/or chart notes when specified by the criteria.

    • PNH: Flow cytometry showing GPI-AP deficiency, including qualifying PNH cell findings when applicable.
    • IgAN: Kidney biopsy confirming primary IgAN and UPCR ≥ 1.5 g/g indicating risk for rapid progression.
    • C3G: Kidney biopsy confirming C3G; proteinuria ≥ 1 g/day or UPCR ≥ 1 g/g; and baseline serum C3 less than 0.85 times the lower limit of normal based on the reference range.
    Documentation Required

    Continuation Response Documentation

    Continuation requests must include documentation of a positive clinical response to Fabhalta. The supporting results must be specific to the member's indication.

    • PNH: Chart notes or medical documentation supporting positive clinical response, such as improved hemoglobin or normalized LDH.
    • IgAN: Laboratory report and/or chart notes supporting positive clinical response.
    • C3G: Laboratory report and/or chart notes showing decreased proteinuria or UPCR from baseline.
    Prior Authorization

    Required Prescriber Specialty

    Fabhalta must be prescribed by or in consultation with the appropriate specialist for the requested indication.

    • PNH: Hematologist.
    • IgAN or C3G: Nephrologist.
    Documentation Required

    Required Non-Formulary Documentation

    Non-formulary exception requests require documentation supporting the indication, dosing, and failure or unsuitability of covered formulary alternatives.

    • Provide diagnostic testing and laboratory results when applicable.
    • Document prior treatment failure, including the severity of any adverse event and the dosage and duration of prior treatment, or document a contraindication to formulary alternatives.
    • The requested indication must be FDA-approved or supported by current compendia or accepted guidelines, and the dose/quantity must be within supported dosing guidance.
    Documentation Required

    Continued-Treatment Documentation

    Continued treatment requires documentation that the member has no unacceptable toxicity or disease progression and is benefiting from the current Fabhalta regimen.

    • For IgAN and C3G, provide evidence of decreased proteinuria or decreased UPCR from baseline.
    • For PNH, provide evidence of positive clinical response, such as improved hemoglobin or normalized LDH.
    Denial Risk

    Preferred PNH Product Requirement

    Fabhalta may be denied for PNH when the preferred-product requirement has not been satisfied and no qualifying clinical exception is documented.

    • The member must have an inadequate response, intolerable adverse event, or contraindication to Epysqli or Ultomiris.
    • Clinical documentation must support why the preferred product cannot be used when applicable.
    Denial Risk

    Failure to Meet Clinical Criteria

    Failure to satisfy any applicable clinical, documentation, specialist, laboratory, response, or safety requirement may result in denial of Fabhalta authorization.

    • Missing or insufficient diagnostic confirmation or laboratory results.
    • Failure to meet indication-specific thresholds or age requirements.
    • Failure to document required RAS inhibitor therapy or an intolerance/contraindication when applicable.
    • Failure to provide required specialist involvement or continuation evidence of benefit and safety.
    Denial Risk

    Prohibited Concomitant Therapy

    Fabhalta must not be used concurrently with therapies prohibited by the criteria for the requested indication. Concurrent use may result in denial.

    • PNH: Do not use with another complement inhibitor, including Empaveli, Piasky, eculizumab, or Ultomiris.
    • IgAN: Do not use with Tarpeyo, Vanrafia, Voyxact, or Filspari.
    Denial Risk

    Criteria Not Met

    Fabhalta is not medically necessary when the member does not meet the applicable criteria set forth in the policy. Members receiving samples or manufacturer patient-assistance medication must still meet the initial approval criteria.

    • Coverage is not established solely because the member has already started therapy through samples or a manufacturer assistance program.
    • The applicable diagnostic, laboratory, clinical, specialist, and treatment requirements must be satisfied.
    Denial Risk

    Non-Formulary Exception Requirements

    A non-formulary exception may be denied when the request lacks support for the indication, dose or quantity, or required failure or unsuitability of covered formulary alternatives.

    • The requested use must be FDA-approved or supported by current compendia or accepted guidelines.
    • The dose and quantity must fall within FDA-approved labeling or supported compendial dosing.
    • Documentation must show that covered formulary alternatives were ineffective, would not be as effective, would have adverse effects, or are contraindicated.
    The applicable laboratory reference ranges determine the lower limit of normal
    Renin-angiotensin system inhibitor therapy
    Therapy categoryRenin-angiotensin system inhibitor therapy
    ACEI definitionAngiotensin-converting enzyme inhibitor
    ARB definitionAngiotensin II receptor blocker
    C3G
    AbbreviationC3G
    Full nameComplement 3 glomerulopathy
    Policy contextFabhalta is evaluated for initial and continued treatment of C3G